These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18451159)

  • 1. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
    Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
    Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Src in prostate cancer.
    Fizazi K
    Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
    Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
    Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
    Rice L; Lepler S; Pampo C; Siemann DW
    Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
    Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
    Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src family kinases differentially influence glioma growth and motility.
    Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
    Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
    Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
    Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
    Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
    Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
    Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
    Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.